Experimental Animals：C57BL/6, BALB/c, 5-6 weeks old, female

Modeling reagent：OVA + Al(OH)3

Modeling method：Sensitization phase: OVA + Al(OH)3 was injected intraperitoneally on days 0, 7, and 14;

                                challenge phase: mice were nebulized with 2% OVA for 30 min daily on days 21 – 25.

IgE Induction in Serum of Asthmatic Mice

Increased  IgE levels in serum of OVA-induced mice compared with controls. Serum was isolated at the end of the experiment and concentrations of OVA-specific IgE (A) and serum total IgE (B) were measured using ELISA.

Airway Histology  in Asthmatic Mouse Model

H&E staining in the lungs of asthmatic mice. In contrast to the  G1 untreated group, the OVA-treated G2 model animals showed asthma-related pathological changes as demonstrated by vascular and peribronchial mixed inflammatory cell infiltration (b) and mucus (a) formation in some bronchi. The above results indicate that OVA could successfully induces asthma in wild-type C57BL/6 mice.

Quantification of Immune Cells in Bronchoalveolar Lavage Fluid (BALF) Of Asthmatic Mice. Asthma was induced in wild-type BALB/c mice using OVA. (A) number of CD45+ cells in BALF; (B) number of eosinophils in BALF; (C) frequency of eosinophils in the CD45+ cell population after sensitization and challenge with OVA, the white blood cell count of mice in the G2 model group was significantly increased compared with the G1 control group, and the number and proportion of eosinophils were significantly increased, suggesting that the model was successfully established. The number of  CD45+ cells and eosinophils were significantly decreased in asthmatic animals treated with higher levels of dexamethasone compared with the untreated asthmatic mice (G2) group.

Detection of IgE levels in serum of asthmaic mice. Serum was taken at the experimental endpoint and concentrations of OVA-specific IgE (A) and total IgE (B) were measured using ELISA. The serum levels of OVA-specific IgE and total IgE in the G2 model group were significantly increased compared with those in the G1 control group, suggesting that the model was successfully established. After administration of different concentrations of dexamethasone (Dex), the specific IgE and total IgE levels were significantly reduced in a dose-dependent manner compared with the G2 group.

H&E staining in the lungs of asthmatic mice. The results showed that there was no inflammatory reaction in the pulmonary airway of G1 control group. Vascular and peribronchial inflammation was significantly increased and mucus secretion levels were increased in the G2  (OVA only) group, suggesting successful modeling of the disease. Administration of different concentrations of dexamethasone to groups G3, reduced inflammatory infiltration and mucus secretion. The results demonstrate that the OVA-induced mouse asthma model can be successfully used to verify the efficacy of corticosteroid immunosuppressive agents.

The asthma model was induced in B-hIL4/hIL4RA mice using OVA. ( A) The number of CD45 + cells in BALF. (B) The number of eosinophils in BALF. (C) The proportion of eosinophils to CD45 + cells. The results showed that after sensitization and challenge with    OVA, the leukocyte infiltration of mice in G2 model group was significantly increased compared with G1 control group, and their eosinophil content was significantly increased, suggesting that the model was successfully established. After administration of dupilumab (in house), the numbers of CD45 + cells and eosinophils were significantly lower compared with the G2 model group.

Detection of IgE levels in serum of asthmatic mouse model. Serum was taken at the end of the experiment and OVA-specific IgE and total IgE levels were measured using ELISA. (A) OVA-specific IgE levels in serum. (B) Total IgE levels in serum. The results showed that the levels of OVA-specific IgE and total IgE in G2 model group were significantly increased compared with G1 control group, suggesting successful modeling. Specific and total IgE levels were significantly lower after administration of dupilumab (in house) drug compared with the G2 modeling group.

Analysis of H&E staining in the lungs of asthmatic mouse models. The results showed that there was no inflammatory cell infiltration in the pulmonary airway of G1 control group. Vascular and peribronchial inflammation (b) were significantly increased and mucus (a) secretion levels were increased in the G2 modeling group, suggesting successful modeling. G3 showed decreased inflammatory infiltration and mucus secretion in dupilumab (in house) -treated mice. The above results demonstrated that OVA could successfully establish an asthma model in B-hIL4/hIL4RA mice for efficacy evaluation.

Criteria of Asthma Mouse Model Establishment

Immune Cell Infiltration in Bronchoalveolar Lavage Fluid (BALF) of Asthmatic Mice

IgE Induction in Serum of Asthmatic Mice

H&E staining in the lungs of asthmatic mice. In contrast to the  G1 untreated group, the HDM-treated G2 model animals showed asthma-related pathological changes as demonstrated by vascular and peribronchial mixed inflammatory cell infiltration (b) and mucus (a) formation in some bronchi. The above results indicate that HDM could successfully induces asthma in wild-type C57BL/6 mice.

Efficacy Assessment of Dupilumab (anti-human IL4RA antibody drug) in Humanized B-hIL4/hIL4RA Mice with Asthma

The asthma model was induced in B-hIL4/hIL4RA mice using HDM. ( A) The number of CD45 + cells in BALF. (B) The number of eosinophils in BALF. (C) The proportion of eosinophils to CD45 + cells. The results showed that after sensitization and challenge with HDM, the leukocyte infiltration of mice in G4 model group was significantly increased compared with G3 control group, and their eosinophil content was significantly increased, suggesting that the model was successfully established. After administration of 25mg/kg dupilumab (in house), the numbers of CD45 + cells and eosinophils were significantly lower compared with the G3 model group. 

Detection of IgE levels in serum of asthmatic mouse model. Serum was taken at the end of the experiment and total IgE levels were measured using ELISA in serum. The results showed that the levels of total IgE in G4 model group were significantly increased compared with G3 control group, suggesting successful modeling. Total IgE levels were significantly lower after administration of dupilumab (in house) drug compared with the G5 modeling group.

References

1. Gandhi, N.A. et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov 15, 35-50 (2016).
2. Audrey Le Floc’h, N.A. et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy, 75(5), 1188-1204(2020)

Establishment of Asthma Mouse Model

Establishment of Asthma Mouse Model： ALT-induced asthma model

Experimental Animals：C57BL/6, Balb/c, B-hIL33/hST2 mice

Modeling reagent：ALT  (Alternaria )

Modeling method：Sensitization—1-5 days

                                  Challenge—19-26days

Quantification of Immune Cells in BALF and total IgE levels in serum of ALT-induced Asthmatic mouse model based on C57BL/6 mice.

(A) number of CD45+ cells, eosinophils and frequency of eosinophils in the CD45+ cell population after sensitization and challenge with ALT. (B) Serum was taken at the experimental endpoint and concentrations of total IgE were measured using ELISA. Values are expressed as mean ± SEM. *p<0.05, **p<0.01.

Histologic Assessment of the lungs of asthmatic mouse model

H&E staining in the lungs of asthmatic mice. ALT-induced asthma model animals showed asthma-related pathological changes as demonstrated by vascular and peribronchial mixed inflammatory cell infiltration  and mucus formation in some bronchi. The score of cells and infiltration of vascular and peribronchial eosinophil were increased after ALT treatment.

References

1. Michael C Yee. Et al. Protease-activated receptor-2 signaling through β-arrestin-2 mediates Alternaria alkaline serine protease- induced airway inflammation. Am J Physiol Lung Cell Mol Physiol. 315(6):L1042-L1057 (2018).

2. Robert J Snelgrove. et al. Alternaria-derived serine protease activity drives IL-33-mediated asthma exacerbations. J Allergy Clin Immunol. 134(3):583-592.e6 (2014).

3. Gandhi, N.A. et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov 15, 35-50 (2016).

4. Pelaia, G., Vatrella, A. & Maselli, R. The potential of biologics for the treatment of asthma. Nat Rev Drug Discov 11, 958-972 (2012).

Product list

References

1. Gandhi, N.A. et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov 15, 35-50 (2016).

2. Pelaia, G., Vatrella, A. & Maselli, R. The potential of biologics for the treatment of asthma. Nat Rev Drug Discov 11, 958-972 (2012).